Patents by Inventor Dieter Gelbmann

Dieter Gelbmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130287782
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and specific uses thereof.
    Type: Application
    Filed: March 28, 2013
    Publication date: October 31, 2013
    Inventors: ANDREAS MEINKE, ESZTER NAGY, MARKUS HANNER, DIETER GELBMANN
  • Patent number: 8529910
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and specific uses thereof.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: September 10, 2013
    Assignee: Intercell Austria AG
    Inventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Dieter Gelbmann
  • Patent number: 8431128
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and specific uses thereof.
    Type: Grant
    Filed: December 12, 2011
    Date of Patent: April 30, 2013
    Assignee: Intercell AG
    Inventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Dieter Gelbmann
  • Patent number: 8349336
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. pyogenes, methods for isolating such antigens and specific uses therefor.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: January 8, 2013
    Assignee: Intercell AG
    Inventors: Andreas Meinke, Eszter Nagy, Birgit Winkler, Dieter Gelbmann
  • Patent number: 8303961
    Abstract: The present invention relates to an isolated nucleic acid molecule encoding a protein, preferably a hyperimmune serum-reactive antigen from Borrelia, a vector comprising such nucleic acid molecule, a host cell comprising such vector, a protein, preferably a hyperimmune serum-reactive antigen from Borrelia, a process for producing such protein, a process for producing a cell which expresses such protein, an antibody that binds to such protein, a hybridoma cell producing such antibody, a method for producing such antibody, a pharmaceutical composition comprising such nucleic acid molecule, protein, or antibody, use of such nucleic acid molecule, protein, or antibody for the manufacture of a medicament, a method for identifying an antagonist capable of reducing or inhibiting the activity of such protein, a method for diagnosis or treatment of an infection with a pathogen causing Lyme disease or an infection with Borrelia burgdorferi s.l.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: November 6, 2012
    Assignee: Intercell AG
    Inventors: Urban Lundberg, Andreas Meinke, Eszter Nagy, Alexander Von Gabain, Birgit Noiges, Dieter Gelbmann, Albina Poljak, Christine Triska
  • Publication number: 20120184710
    Abstract: The present invention relates to an isolated nucleic acid molecule encoding a protein, preferably a hyperimmune serum-reactive antigen from Borrelia, a vector comprising such nucleic acid molecule, a host cell comprising such vector, a protein, preferably a hyperimmune serum-reactive antigen from Borrelia, a process for producing such protein, a process for producing a cell which expresses such protein, an antibody that binds to such protein, a hybridoma cell producing such antibody, a method for producing such antibody, a pharmaceutical composition comprising such nucleic acid molecule, protein, or antibody, use of such nucleic acid molecule, protein, or antibody for the manufacture of a medicament, a method for identifying an antagonist capable of reducing or inhibiting the activity of such protein, a method for diagnosis or treatment of an infection with a pathogen causing Lyme disease or an infection with Borrelia burgdorferi s.l.
    Type: Application
    Filed: March 2, 2012
    Publication date: July 19, 2012
    Applicant: INTERCELL AG
    Inventors: URBAN LUNDBERG, ANDREAS MEINKE, ESZTER NAGY, ALEXANDER VON GABAIN, BIRGIT NOIGES, DIETER GELBMANN, ALBINA POLJAK, CHRISTINE TRISKA
  • Publication number: 20120082674
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and specific uses thereof.
    Type: Application
    Filed: December 12, 2011
    Publication date: April 5, 2012
    Applicant: Intercell AG
    Inventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Dieter Gelbmann
  • Patent number: 8129165
    Abstract: The present invention relates to isolated nucleic acid molecules which encode a protein, isolated nucleic acid molecules which encode a hyperimmune serum reactive antigen, a vector which comprises such nucleic acid molecule, a host cell comprising such vector, a hyperimmune reactive antigen from Borrelia species, proteins which are preferably hyperimmune serum reactive antigens, hyperimmune serum reactive antigens, antigens, a process for producing such proteins, hyperimmune serum reactive antigens or antigens, a process for producing a cell which expresses such protein, hyperimmune serum reactive antigen or antigen, an antibody binding to such protein, hyperimmune serum reactive antigen or antigen, a hybridoma cell producing such antibody, methods for producing such antibody, a pharmaceutical composition comprising such nucleic acid molecule, protein, hyperimmune serum reactive antigen, antigen or antibody, the use of such nucleic acid molecule, protein, hyperimmune serum reactive antigen, antigen or antibod
    Type: Grant
    Filed: September 14, 2007
    Date of Patent: March 6, 2012
    Assignee: Intercell AG
    Inventors: Urban Lundberg, Andreas Meinke, Eszter Nagy, Alexander von Gabain, Birgit Noiges, Dieter Gelbmann, Albina Poljak, Christine Triska
  • Publication number: 20110243978
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and specific uses thereof.
    Type: Application
    Filed: March 28, 2011
    Publication date: October 6, 2011
    Applicant: INTERCELL AG
    Inventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Dieter Gelbmann
  • Publication number: 20100255034
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. pyogenes, methods for isolating such antigens and specific uses therefor.
    Type: Application
    Filed: December 18, 2009
    Publication date: October 7, 2010
    Applicant: INTERCELL AG
    Inventors: Andreas Meinke, Eszter Nagy, Birgit Winkler, Dieter Gelbmann
  • Publication number: 20100136039
    Abstract: The present invention relates to isolated nucleic acid molecules which encode a protein, isolated nucleic acid molecules which encode a hyperimmune serum reactive antigen, a vector which comprises such nucleic acid molecule, a host cell comprising such vector, a hyperimmune reactive antigen from Borrelia species, proteins which are preferably hyperimmune serum reactive antigens, hyperimmune serum reactive antigens, antigens, a process for producing such proteins, hyperimmune serum reactive antigens or antigens, a process for producing a cell which expresses such protein, hyperimmune serum reactive antigen or antigen, an antibody binding to such protein, hyperimmune serum reactive antigen or antigen, a hybridoma cell producing such antibody, methods for producing such antibody, a pharmaceutical composition comprising such nucleic acid molecule, protein, hyperimmune serum reactive antigen, antigen or antibody, the use of such nucleic acid molecule, protein, hyperimmune serum reactive antigen, antigen or antibod
    Type: Application
    Filed: September 14, 2007
    Publication date: June 3, 2010
    Applicant: Intercell AG
    Inventors: Urban Lundberg, Andreas Meinke, Eszter Nagy, Alexander von Gabain, Birgit Noiges, Dieter Gelbmann, Albina Poljak, Christine Triska
  • Patent number: 7638136
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. pyogenes, methods for isolating such antigens and specific uses therefore.
    Type: Grant
    Filed: March 2, 2004
    Date of Patent: December 29, 2009
    Assignee: Intercell AG
    Inventors: Andreas Meinke, Eszter Nagy, Birgit Winkler, Dieter Gelbmann
  • Publication number: 20080175856
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and specific uses thereof.
    Type: Application
    Filed: May 26, 2004
    Publication date: July 24, 2008
    Applicant: Intercell AG
    Inventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Dieter Gelbmann
  • Publication number: 20060194751
    Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S.
    Type: Application
    Filed: March 2, 2004
    Publication date: August 31, 2006
    Applicant: InterCell AG
    Inventors: Andreas Meinke, Eszter Nagy, Birgit Winkler, Dieter Gelbmann
  • Publication number: 20050220788
    Abstract: The present invention provides the use of molecules, which interact with the haptoglobin receptor ligand binding for the preparation of a medicament to prevent and treat Staphylococcus infection.
    Type: Application
    Filed: June 18, 2003
    Publication date: October 6, 2005
    Applicant: Intercell AG
    Inventors: Eszter Nagy, Agnieszka Dryla, Dieter Gelbmann